Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).
|Number of pages||9|
|Journal||Alzheimer's & dementia : the journal of the Alzheimer's Association|
|Publication status||Published - Mar 2008|
Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D. D., ... Passmore, P. (2008). The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimer's & dementia : the journal of the Alzheimer's Association, 4(2), 145-53. https://doi.org/10.1016/j.jalz.2008.02.001